Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 84-91 |
| Seitenumfang | 8 |
| Fachzeitschrift | Pharmacopsychiatry |
| Jahrgang | 52 |
| Ausgabenummer | 2 |
| Frühes Online-Datum | 31 Jan. 2018 |
| Publikationsstatus | Veröffentlicht - 2019 |
Abstract
Introduction Benzodiazepines and related drugs (BZDR) should be avoided in patients with cognitive impairment. We evaluated the relationship between a BZDR treatment and the health status of patients with Alzheimer's disease (AD). Methods Cross-sectional study in 395 AD patients using bivariate and multiple logistic analyses to assess correlations between the prescription of BZDR and patients' characteristics (cognitive and functional capacity, health-related quality of life (HrQoL), neuropsychiatric symptoms). Results BZDR were used in 12.4% (n=49) of all participants. In bivariate analyses, the prescription was associated with a lower HrQoL, a higher need of care, and the presence of anxiety. Multivariate models revealed a higher risk of BZDR treatment in patients with depression (OR 3.85, 95% CI: 1.45 - 10.27). Community-dwelling participants and those treated by neurologists/psychiatrists had a lower risk of receiving BZDR (OR 0.33, 95% CI: 0.12 - 0.89 and OR 0.16, 95% CI: 0.07 - 0.36). Discussion The inappropriate use of BZDR conflicts with national and international guidelines. We suggest evaluating indications and treatment duration and improving the knowledge of alternative therapies in healthcare institutions.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Psychiatrie und psychische Gesundheit
- Medizin (insg.)
- Pharmakologie (medizinische)
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Pharmacopsychiatry, Jahrgang 52, Nr. 2, 2019, S. 84-91.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease
AU - Hessmann, Philipp
AU - Dodel, Richard
AU - Baum, Erika
AU - Müller, Matthias J.
AU - Paschke, Greta
AU - Kis, Bernhard
AU - Zeidler, Jan
AU - Klora, Mike
AU - Reese, Jens Peter
AU - Balzer-Geldsetzer, Monika
N1 - Funding information: This study was supported by an unrestricted grant from the Ernst-and-Margot-Faber-Stiftung, Marburg, Germany. This study was supported ?y an unrestricted grant from the Ernst-and-Margot-Faer-Stiftung, Mar?urg, Germany.
PY - 2019
Y1 - 2019
N2 - Introduction Benzodiazepines and related drugs (BZDR) should be avoided in patients with cognitive impairment. We evaluated the relationship between a BZDR treatment and the health status of patients with Alzheimer's disease (AD). Methods Cross-sectional study in 395 AD patients using bivariate and multiple logistic analyses to assess correlations between the prescription of BZDR and patients' characteristics (cognitive and functional capacity, health-related quality of life (HrQoL), neuropsychiatric symptoms). Results BZDR were used in 12.4% (n=49) of all participants. In bivariate analyses, the prescription was associated with a lower HrQoL, a higher need of care, and the presence of anxiety. Multivariate models revealed a higher risk of BZDR treatment in patients with depression (OR 3.85, 95% CI: 1.45 - 10.27). Community-dwelling participants and those treated by neurologists/psychiatrists had a lower risk of receiving BZDR (OR 0.33, 95% CI: 0.12 - 0.89 and OR 0.16, 95% CI: 0.07 - 0.36). Discussion The inappropriate use of BZDR conflicts with national and international guidelines. We suggest evaluating indications and treatment duration and improving the knowledge of alternative therapies in healthcare institutions.
AB - Introduction Benzodiazepines and related drugs (BZDR) should be avoided in patients with cognitive impairment. We evaluated the relationship between a BZDR treatment and the health status of patients with Alzheimer's disease (AD). Methods Cross-sectional study in 395 AD patients using bivariate and multiple logistic analyses to assess correlations between the prescription of BZDR and patients' characteristics (cognitive and functional capacity, health-related quality of life (HrQoL), neuropsychiatric symptoms). Results BZDR were used in 12.4% (n=49) of all participants. In bivariate analyses, the prescription was associated with a lower HrQoL, a higher need of care, and the presence of anxiety. Multivariate models revealed a higher risk of BZDR treatment in patients with depression (OR 3.85, 95% CI: 1.45 - 10.27). Community-dwelling participants and those treated by neurologists/psychiatrists had a lower risk of receiving BZDR (OR 0.33, 95% CI: 0.12 - 0.89 and OR 0.16, 95% CI: 0.07 - 0.36). Discussion The inappropriate use of BZDR conflicts with national and international guidelines. We suggest evaluating indications and treatment duration and improving the knowledge of alternative therapies in healthcare institutions.
KW - benzodiazepines
KW - dementia
KW - depression
KW - neuropsychiatric specialists
UR - http://www.scopus.com/inward/record.url?scp=85041563500&partnerID=8YFLogxK
U2 - 10.1055/s-0044-100523
DO - 10.1055/s-0044-100523
M3 - Article
C2 - 29388173
AN - SCOPUS:85041563500
VL - 52
SP - 84
EP - 91
JO - Pharmacopsychiatry
JF - Pharmacopsychiatry
SN - 0176-3679
IS - 2
ER -